Effect of Infliximab Drug Monitoring on 54 Weeks Treatment Outcome of Children with Crohn's Disease
DOI:10.13748/j.cnki.issn1007-7693.20232251
- VernacularTitle:英夫利西单抗药物监测对儿童克罗恩病患者54周治疗结局的影响
- Author:
FANG Youhong
1
,
2
;
LUO Youyou
1
,
2
;
CHENG Qi
1
,
2
;
YU Jindan
1
,
2
;
CHEN Jie
1
,
2
Author Information
1. Department of Gastroenterology, Children'
2. s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China
- Publication Type:Journal Article
- Keywords:
Crohn's disease / children / therapeutic drug monitoring / infliximab
- From:
Chinese Journal of Modern Applied Pharmacy
2023;40(22):3152-3157
- CountryChina
- Language:Chinese
-
Abstract:
Abstract:OBJECTIVE To investigate the effect of infliximab through concentration and antibody monitoring on the clinical outcome of children with Crohn's disease after 54 weeks of treatment. METHODS A retrospective analysis was conducted with clinical data of pediatric patients aged 6-17 years who were diagnosed with Crohn's disease at Children's Hospital, Zhejiang University School of Medicine from August 2017 to March 2023. They were divided into a reactive and a proactive monitoring group according to the monitoring method. The mucosal healing rate, disease activity, and laboratory indicators were compared after 54 weeks of treatment. RESULTS There were 77 pediatric patients with Crohn's disease included, with 34 patients from the reactive therapeutic drug monitoring group and 43 from the proactive therapeutic drug monitoring group, including 48 males and 29 females. At 54 weeks, the mucosal healing rate in the proactive therapeutic drug monitoring group was higher than that in the reactive therapeutic drug monitoring group, which was 80%(24/30) and 46.43%(13/28), respectively. The two groups had a statistical difference(P=0.01). The total clinical remission rate at 54 weeks was 84.42%(65/77), while the clinical remission rates at 54 weeks were 76.47%(26/34) in the reactive therapeutic drug monitoring group and 90.70%(39/43) in the proactive therapeutic drug monitoring group, respectively. The two groups had no statistical difference. The improvement of hypersensitive C-reactive protein, erythrocyte sedimentation rate, and serum albumin level in the proactive monitoring group was greater than in the reactive monitoring group. There was no statistical difference in the production rate of antibodies to infliximab between the two groups. CONCLUSION Proactive therapeutic drug monitoring in detecting through concentration of infliximab and antibodies may improve the mucosal healing rate compared with reactive therapeutic drug monitoring after 54 weeks of infliximab treatment.
